Phase II Study of Docetaxel in Patients with Pancreatic Cancer Previously Untreated with Cytotoxic Chemotherapy

摘要: In this study, we estimated the response rate, duration of response, and type, severity reversibility toxicities in patients with Stage IV adenocarcinoma pancreas treated docetaxel. Twenty-one locally advanced or metastatic pancreatic cancer, previously untreated surgery radiation alone, were 100 mg/m2 docetaxel as a 1 hr infusion once every 21 days. All pretreated dexamethasone diphenhydramine. Twenty assessable for both toxicity. One patient was toxicity alone. However, all assessed survival. The major side effect drug neutropenia, which required dose reduction to 75 approximately half patients. Nine hospitalized neutropenic fever. Fluid retention not significant problem. had partial lasting weeks 7 stable disease. remaining progressi...